Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states.
The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled in the BENEFIT-HF trial, the landmark heart failure study evaluating Barostim in a significantly expanded patient population initiated earlier this year.
"We are pleased to receive this Medicare Advantage coverage policy from Humana, which represents the first coverage policy for Barostim and marks an important milestone in our efforts to expand access to the therapy for patients living with heart failure," said Kevin Hykes, President and Chief Executive Officer of CVRx. "Humana's policy reflects continued progress in educating payers on the clinical outcomes and patient benefits of Barostim therapy. We believe this policy validates our commercial strategy, supports ongoing discussions with other regional and national payers, and will help accelerate adoption of Barostim through more consistent coverage."
This coverage policy follows two other positive reimbursement developments for Barostim this year. Effective Jan. 1, 2026, Category I CPT codes went into effect for the Barostim procedure. In addition, that same month, the Centers for Medicare & Medicaid Services (CMS) approved Category B IDE coverage for patients enrolled in the BENEFIT-HF trial.